Capo, V. Et Al. 2018. Efficacy of lentivirus-mediated gene therapy in an Omenn syndrome recombination-activating gene 2 mouse model is not hindered by inflammation and immune dysregulation. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY , vol.142, no.3 , 928-949.

Capo, V., Castiello, M. C., Fontana, E., Penna, S., Bosticardo, M., Draghici, E., ... Poliani, L. P.(2018). Efficacy of lentivirus-mediated gene therapy in an Omenn syndrome recombination-activating gene 2 mouse model is not hindered by inflammation and immune dysregulation. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY , vol.142, no.3, 928-949.

Capo, Valentina Et Al. "Efficacy of lentivirus-mediated gene therapy in an Omenn syndrome recombination-activating gene 2 mouse model is not hindered by inflammation and immune dysregulation," JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY , vol.142, no.3, 928-949, 2018

Capo, Valentina Et Al. "Efficacy of lentivirus-mediated gene therapy in an Omenn syndrome recombination-activating gene 2 mouse model is not hindered by inflammation and immune dysregulation." JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY , vol.142, no.3, pp.928-949, 2018

Capo, V. Et Al. (2018) . "Efficacy of lentivirus-mediated gene therapy in an Omenn syndrome recombination-activating gene 2 mouse model is not hindered by inflammation and immune dysregulation." JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY , vol.142, no.3, pp.928-949.

@article{article, author={Valentina Capo Et Al. }, title={Efficacy of lentivirus-mediated gene therapy in an Omenn syndrome recombination-activating gene 2 mouse model is not hindered by inflammation and immune dysregulation}, journal={JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY}, year=2018, pages={928-949} }